ADAP vs. HUMA, STOK, ERAS, ANAB, XERS, MNMD, AKBA, MLYS, TRDA, and RNAC
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Humacyte (HUMA), Stoke Therapeutics (STOK), Erasca (ERAS), AnaptysBio (ANAB), Xeris Biopharma (XERS), Mind Medicine (MindMed) (MNMD), Akebia Therapeutics (AKBA), Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.
Adaptimmune Therapeutics vs.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Humacyte has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Adaptimmune Therapeutics' return on equity of -74.15% beat Humacyte's return on equity.
Adaptimmune Therapeutics received 282 more outperform votes than Humacyte when rated by MarketBeat users. However, 67.31% of users gave Humacyte an outperform vote while only 63.02% of users gave Adaptimmune Therapeutics an outperform vote.
Humacyte has lower revenue, but higher earnings than Adaptimmune Therapeutics. Humacyte is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Humacyte had 5 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 10 mentions for Humacyte and 5 mentions for Adaptimmune Therapeutics. Humacyte's average media sentiment score of 0.79 beat Adaptimmune Therapeutics' score of 0.26 indicating that Humacyte is being referred to more favorably in the news media.
Adaptimmune Therapeutics presently has a consensus price target of $2.79, suggesting a potential upside of 372.46%. Humacyte has a consensus price target of $13.71, suggesting a potential upside of 199.44%. Given Adaptimmune Therapeutics' higher possible upside, equities research analysts plainly believe Adaptimmune Therapeutics is more favorable than Humacyte.
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Adaptimmune Therapeutics has a beta of 2.24, meaning that its share price is 124% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
Summary
Adaptimmune Therapeutics and Humacyte tied by winning 9 of the 18 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADAP) was last updated on 2/1/2025 by MarketBeat.com Staff
